Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance …
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study,
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts
Purpose Although the life expectancy of patients with follicular lymphoma (FL) has
increased, little is known of their causes of death (CODs) in the rituximab era. Patients and …
increased, little is known of their causes of death (CODs) in the rituximab era. Patients and …
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
G Thanarajasingam, LM Minasian… - The Lancet …, 2022 - thelancet.com
Remarkable improvements in outcomes for many haematological malignancies have been
driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted …
driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted …
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
In follicular lymphoma (FL), no prognostic index has been built based solely on a cohort of
patients treated with initial immunochemotherapy. There is currently a need to define …
patients treated with initial immunochemotherapy. There is currently a need to define …
Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials
Purpose Selection bias in clinical trials has consequences for scientific validity and
applicability of study results to the general population. There is concern that patients with …
applicability of study results to the general population. There is concern that patients with …
Lack of intrafollicular memory CD4+ T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma
P Mondello, A Fama, MC Larson, AL Feldman… - Blood cancer …, 2021 - nature.com
Despite a characteristic indolent course, a substantial subset of follicular lymphoma (FL)
patients has an early relapse with a poor outcome. Cells in the microenvironment may be a …
patients has an early relapse with a poor outcome. Cells in the microenvironment may be a …
The advanced-stage hodgkin lymphoma international prognostic index: Development and validation of a clinical prediction model from the HoLISTIC consortium
AM Rodday, SK Parsons, JN Upshaw… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE The International Prognostic Score (IPS) has been used in classic Hodgkin
lymphoma (cHL) for 25 years. However, analyses have documented suboptimal …
lymphoma (cHL) for 25 years. However, analyses have documented suboptimal …
Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
PURPOSE In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occur
within the first 2 years of diagnosis. We sought to define the rate and outcome of late …
within the first 2 years of diagnosis. We sought to define the rate and outcome of late …
Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation
Immunochemotherapy has been the mainstay of treatment for newly diagnosed diffuse large
B-cell lymphoma (ndDLBCL) yet is inadequate for many patients. In this work, we perform …
B-cell lymphoma (ndDLBCL) yet is inadequate for many patients. In this work, we perform …
Harnessing multi-source data for individualized care in Hodgkin Lymphoma
SK Parsons, AM Rodday, JN Upshaw, CD Scharman… - Blood Reviews, 2024 - Elsevier
Hodgkin lymphoma is a rare, but highly curative form of cancer, primarily afflicting
adolescents and young adults. Despite multiple seminal trials over the past twenty years …
adolescents and young adults. Despite multiple seminal trials over the past twenty years …